KRTX - Karuna's Drug Mechanism Of Action Established After Latest Positive Trial Readout In Schizophrenia Study
Karuna Therapeutics (KRTX) announced that it had achieved positive results from its phase 2 study using KarXT to treat acute psychosis in patients with schizophrenia. There was a substantial improvement achieved in the primary endpoint of the study. This was not only an important finding for a new class of drugs treating central nervous system ((CNS)) disorders, but in the ability to overcome the harsh side effects of first and second generation antipsychotics that are given as current standard of care ((SOC)) for this patient population. The best part of all is that